Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Aspirin Prevention of ColorectalCancer: Focus on NF-ÎºB Signalling and the Nucleolus Overwhelming evidence indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have anti-tumour activity and the potential to prevent cancer, particularly colorectalcancer. However, the mechanisms underlying this effect remain hypothetical. Dysregulation of the nuclear factor-kappaB (NF-κB) transcription factor is a common event in many cancer types which contributes to tumour (...) initiation and progression by driving expression of pro-proliferative/anti-apoptotic genes. In this review, we will focus on the current knowledge regarding NSAID effects on the NF-κB signalling pathway in pre-cancerous and cancerous lesions, and the evidence that these effects contribute to the anti-tumour activity of the agents. The nuclear organelle, the nucleolus, is emerging as a central regulator of transcription factor activity and cell growth and death. Nucleolar function is dysregulated
Scaffold Proteins in GastrointestinalTumors as a Shortcut to Oncoprotein Activation The development of cancer involves uncontrolled cell proliferation, and multiple signaling pathways that regulate cell proliferation have been found to be dysregulated in cancers. Extracellular signal-regulated protein kinase (ERK) is one of three major subtypes in the mitogen-activated protein kinase (MAPK) families. The MAPK/ERK pathway (RAS/RAF1/MEK/ERK) plays an important part in promoting cell (...) proliferation in response to growth factors, thereby serving as a driving signal in gastrointestinal (GI) tumors. In contrast, the p53 tumor suppressor functions as a "guardian of the genome" and stops cell proliferation when oncogenic signaling is activated.Both pathways constrain each other in healthy GI epithelium, facilitating controlled proliferation that is essential for tissue repair and regeneration. However, in GItumors, the MAPK/ERK and p53 pathways are commonly dysregulated, in part due
The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumormalignancy in colorectalcarcinomaColorectalcancer is the most common malignancy of the gastrointestinal tract with very high mortality. One of the most distinguishing features for the establishment of an epithelial-mesenchymal transition phenotype is the alteration of mesenchymal markers expression and structural adhesion proteins. We evaluated the significance of vimentin (...) and fibronectin gene expression in relation to invasion and metastasis in CRC patients. Tissue specimens were collected consecutively from forty-five colorectalcarcinoma patients during surgeries. Tissues were divided into two separate parts for pathological and molecular assays. In order to histological staging, tissue sections were prepared from formalin-fixed paraffin-embedded blocks and stained with Hematoxylin and Eosin. To quantify gene expression, specimens were dissected and homogenized. Moreover
ASCO: practice changing studies in gastrointestinalcancer 28761760 2017 08 01 2059-7029 2 3 2017 ESMO open ESMO Open ASCO: practice changing studies in gastrointestinalcancer. e000228 10.1136/esmoopen-2017-000228 Prager Gerald G Department of Medicine, Comprehensive Cancer Center, Medical University Vienna, Austria, Vienna, Austria. eng Journal Article 2017 07 05 England ESMO Open 101690685 2059-7029 gastrointestinalcancer Competing interests: None declared. 2017 06 01 2017 8 2 6 0 2017 8 2
Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and ColorectalCancer Survivors: The SWORD Study, a Randomized Controlled Trial Purpose Fear of cancer recurrence (FCR) is a common problem experienced by cancer survivors. Approximately one third of survivors report high FCR. This study aimed to evaluate whether blended cognitive behavior therapy (bCBT) can reduce the severity of FCR in cancer survivors curatively treated for breast, prostate (...) , or colorectalcancer. Patients and Methods This randomized controlled trial included 88 cancer survivors with high FCR (Cancer Worry Scale score ≥ 14) from 6 months to 5 years after cancer treatment. Participants were randomly allocated (ratio 1:1, stratified by cancer type) to receive bCBT, including five face-to face and three online sessions (n = 45) or care as usual (CAU; n = 43). Participants completed questionnaires at baseline (T0) and 3 months later (T1). The intervention group completed bCBT
The clinical effectiveness of different surveillance strategies to prevent colorectalcancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different surveillance strategies to prevent colorectalcancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different (...) surveillance strategies to prevent colorectalcancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A, Perera S, Wood J, Miles A, Wardle J, Kearns B, Tappenden P, Myles J, Veitch A & Duffy S W Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation
Clinical Calculator for Early Mortality in Metastatic ColorectalCancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectalcancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled (...) in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectalcancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.
Extracolonic Cancer in Inflammatory BowelDisease: Data from the GETECCU Eneida Registry The objective of this study was (a) To know the prevalence and distribution of extracolonic cancer (EC) in patients with inflammatory boweldisease (IBD); (b) To estimate the incidence rate of EC; (c) To evaluate the association between EC and treatment with immunosuppressants and anti-tumor necrosis factor (TNF) agents.This was an observational cohort study.IBD and inclusion in the ENEIDA Project
Effect of Intrathecally Administered Ketamine, Morphine, and Their Combination Added to Bupivacaine in Patients Undergoing Major AbdominalCancer Surgery a Randomized, Double-Blind Study Effective postoperative pain control reduces postoperative morbidity. In this study, we investigated the effects of intrathecal morphine, ketamine, and their combination with bupivacaine for postoperative analgesia in major abdominalcancer surgery.Prospective, randomized, double-blind.Academic medical (...) with group M until six hours postoperation. No other side effects were observed.Adding intrathecal ketamine 0.1 mg/kg to morphine 0.3 mg in patients who underwent major abdominalcancer surgery reduced the total postoperative morphine consumption in comparison with either drug alone, with an overall good postoperative analgesia in all groups, with no side effects apart from sedation.
Another brick in the large wall against colorectalcancer: a commentary on effectiveness of screening colonoscopy 28713863 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Another brick in the large wall against colorectalcancer: a commentary on effectiveness of screening colonoscopy. 59 10.21037/tgh.2017.06.02 Glazer Yair Y Department of Surgery A, Soroka University Medical Center, Beer Sheva, Israel. Perry Zvi H ZH Department of Surgery (...) A, Soroka University Medical Center, Beer Sheva, Israel. Department of Epidemiology, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Avital Itzhak I Department of Surgery A, Soroka University Medical Center, Beer Sheva, Israel. Soroka University Comprehensive Cancer Center, Beer-Sheva, Israel. Department of Healthcare Sciences, Ben-Gurion University, Beer-Sheva, Israel. eng Editorial Comment 2017 06 30 China Transl Gastroenterol Hepatol 101683450 2415-1289 Gut. 2016 Oct 12;: 27733426 Conflicts
Mortality and Survival after Surgical Treatment of ColorectalCancer in Patients Aged over 80 Years The purpose of this study was to identify the clinical factors and tumor characteristics that predict the outcome of colorectalcancer patients aged >80 years.The data of 186 patients aged >80 years with colorectalcancer were collected from a computer database, and the variables were analyzed by both uni- and multivariate analyses.The 30-day mortality was 4% and the 90-day mortality 10%. The 1 (...) -year survival was 76%, and 27 (61%) of the 44 deaths were unrelated to cancer. The overall 5-year survival was 36%, the median survival 38 months, and the cancer-specific survival 40%. The recurrence rate after radical surgery was 22% and it was not affected by age. Kaplan-Meier estimates indicated that age, number of underlying diseases, radical operation, Union for International Cancer Control stage of the tumor, tumor size, number of lymph nodes involved, venous invasion, and recurrent disease
Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectalcancer - third line Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectalcancer – third line | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search (...) will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectalcancer – third line Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectalcancer – third line June 2017 The combination of atezolizumab (Tecentriq), given by injection, and cobimetinib (Cotellic), given orally, is being developed to increase the options available
colorectalcancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015.Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient.The primary end point was overall survival. Secondary objectives included progression-free survival and overall (...) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic ColorectalCancer: A Randomized Clinical Trial. Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectalcancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown.To determine if the addition
Update on anti-tumor necrosis factor agents and other new drugs for inflammatory boweldisease. The treatment of inflammatory boweldisease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years
were determined in both validation cohorts at 1, 5, and 10 years.Results The final models included the following variables in men and women: age, deprivation score, cancer stage, cancer grade, smoking status, colorectal surgery, chemotherapy, family history of bowelcancer, raised platelet count, abnormal liver function, cardiovascular disease, diabetes, chronic renal disease, chronic obstructive pulmonary disease, prescribed aspirin at diagnosis, and prescribed statins at diagnosis. Improved (...) survival in women was associated with younger age, earlier stage of cancer, well or moderately differentiated cancer grade, colorectalcancer surgery (adjusted hazard ratio 0.50), family history of bowelcancer (0.62), and prescriptions for statins (0.77) and aspirin (0.83) at diagnosis, with comparable results for men. The risk equations were well calibrated, with predicted risks closely matching observed risks. Discrimination was good in men and women in both validation cohorts. For example, the five
Technical success and short-term results of surgical treatment of gastrointestinal stromal tumors: an experience of three centers Gastrointestinal stromal tumors (GIST) comprise about 80% of gastrointestinal sarcomas. In patients with localized disease, surgery is considered as "Gold Standard" treatment. Organ-sparing radical en-block resection is widely accepted practice. Since lymph node dissection is not routinely indicated, minimally invasive approach is of particular interest. The aim (...) of this study is to investigate the short-term outcomes of different surgical treatment of GISTs.We analyzed data of 116 patients who received surgical treatment for localized forms of GIST. Tumors were located in the stomach in 87 (75%) cases, in the small intestine in 26 (22.4%) cases, and extragastrointestinal GISTs were found in 3 (2.6%) patients. Four different approaches were used-open surgery (OpS, n=48), laparoscopic surgery (LS, n=40), endoscopic procedures (EP, n=22) and hybrid rendezvous (HR, n=6
Clinical responses to ERK inhibition in BRAFV600E-mutant colorectalcancer predicted using a computational model Approximately 10% of colorectalcancers harbor BRAFV600E mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) studies of cetuximab (EGFR), vemurafenib (BRAF (...) ), cobimetinib (MEK), and GDC-0994 (ERK) combinations. Preclinical data was used to develop a mechanism-based computational model linking cell surface receptor (EGFR) activation, the MAPK signaling pathway, and tumor growth. Clinical predictions of anti-tumor activity were enabled by the use of tumor response data from three Phase 1 clinical trials testing combinations of EGFR, BRAF, and MEK inhibitors. Simulated responses to GDC-0994 monotherapy (overall response rate = 17%) accurately predicted results
Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for ColorectalCancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial Colorectalcancer (CRC) screening is underused, especially among vulnerable populations. Decision aids and patient navigation are potentially complementary interventions for improving CRC screening rates, but their combined effect on screening completion is unknown.To determine the combined effect of a CRC screening decision
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Tr Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). Patients and Methods (...) for the probability of surviving beyond 10 years. Conclusion This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of the use of imatinib, in a large population of patients with advanced GIST. With a long follow-up, 6% of patients are long-term progression free and 13% are survivors. Among clinical prognostic factors, only performance status, KIT mutation, and size of largest lesion predicted long-term outcome, likely pointing to a lower burden of disease. Genomic